Beta-blocking agents and plasma lipids: an update.
D000433:1-Propanol / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001262:Atenolol / Q000494:pharmacology; D008078:Cholesterol, LDL / Q000378:metabolism; D003327:Coronary Disease / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D053439:Lipoproteins, HDL2; D008077:Lipoproteins, LDL / Q000097:blood; D010096:Oxprenolol / Q000494:pharmacology; D010394:Penbutolol / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D013015:Sotalol / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D008078:Cholesterol, LDL; D008055:Lipids; D008075:Lipoproteins, HDL; D053439:Lipoproteins, HDL2; D008077:Lipoproteins, LDL; D001262:Atenolol; D010096:Oxprenolol; D010394:Penbutolol; D000433:1-Propanol; D013015:Sotalol; D010869:Pindolol